TW202309299A - 鑒定癌細胞中藥物敏感基因和耐藥基因的方法 - Google Patents

鑒定癌細胞中藥物敏感基因和耐藥基因的方法 Download PDF

Info

Publication number
TW202309299A
TW202309299A TW111126186A TW111126186A TW202309299A TW 202309299 A TW202309299 A TW 202309299A TW 111126186 A TW111126186 A TW 111126186A TW 111126186 A TW111126186 A TW 111126186A TW 202309299 A TW202309299 A TW 202309299A
Authority
TW
Taiwan
Prior art keywords
sgrna
ibar
cancer cell
library
sequence
Prior art date
Application number
TW111126186A
Other languages
English (en)
Chinese (zh)
Inventor
鵬飛 袁
鳴 金
永建 張
紅豔 申
玲 楊
娜 劉
美華 蘇
雅茹 鄭
玉蘭 李
Original Assignee
大陸商北京輯因醫療科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商北京輯因醫療科技有限公司 filed Critical 大陸商北京輯因醫療科技有限公司
Publication of TW202309299A publication Critical patent/TW202309299A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111126186A 2021-07-12 2022-07-12 鑒定癌細胞中藥物敏感基因和耐藥基因的方法 TW202309299A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
WOPCT/CN2021/105822 2021-07-12
WOPCT/CN2021/105816 2021-07-12
CN2021105822 2021-07-12
CN2021105816 2021-07-12

Publications (1)

Publication Number Publication Date
TW202309299A true TW202309299A (zh) 2023-03-01

Family

ID=84919026

Family Applications (2)

Application Number Title Priority Date Filing Date
TW111126186A TW202309299A (zh) 2021-07-12 2022-07-12 鑒定癌細胞中藥物敏感基因和耐藥基因的方法
TW111126187A TW202317523A (zh) 2021-07-12 2022-07-12 結直腸癌治療的生物標記

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111126187A TW202317523A (zh) 2021-07-12 2022-07-12 結直腸癌治療的生物標記

Country Status (2)

Country Link
TW (2) TW202309299A (fr)
WO (2) WO2023284735A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117210568B (zh) * 2023-10-30 2024-06-21 云南省肿瘤医院(昆明医科大学第三附属医院) 一种检测家族遗传性结直肠癌的snp标志物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112522408A (zh) * 2013-09-23 2021-03-19 芝加哥大学 关于dna损伤制剂用于癌症治疗的方法和组合物
WO2015100257A1 (fr) * 2013-12-23 2015-07-02 The General Hospital Corporation Procédés et dosages pour la détermination d'une fonction de voie brca1 réduite dans une cellule cancéreuse
JP7187308B2 (ja) * 2015-09-30 2022-12-12 バーテックス ファーマシューティカルズ インコーポレイテッド Ｄｎａ損傷剤とａｔｒ阻害剤との組み合わせを使用する、がんを処置するための方法
JOP20190197A1 (ar) * 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
MX2020006866A (es) * 2017-12-27 2020-11-11 Tesaro Inc Metodos para tratar el cancer.
WO2019133711A1 (fr) * 2017-12-29 2019-07-04 Vertex Pharmaceuticals Incorporated Méthodes de traitement du cancer faisant appel à un inhibiteur d'atr
CN110343724B (zh) * 2018-04-02 2021-10-12 北京大学 用于筛选和鉴定功能性lncRNA的方法
CN111334531A (zh) * 2018-12-18 2020-06-26 博雅辑因（北京）生物科技有限公司 高信噪比阴性遗传筛选方法
KR20210106527A (ko) * 2018-12-20 2021-08-30 페킹 유니버시티 바코드화 가이드 rna 구축물을 사용한 고효율의 유전자 스크리닝을 위한 조성물 및 방법
CN111349654B (zh) * 2018-12-20 2023-01-24 北京大学 使用加标签的向导rna构建体进行高效基因筛选的组合物和方法
CN110570922B (zh) * 2019-07-19 2022-06-10 浙江大学 一种评估hr缺陷模型及应用
KR102580824B1 (ko) * 2019-10-30 2023-09-21 (재)록원바이오융합연구재단 Parp 저해제에 대한 반응성 결정방법
CN113025713B (zh) * 2021-02-23 2022-11-22 浙江东睿生物科技有限公司 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用

Also Published As

Publication number Publication date
TW202317523A (zh) 2023-05-01
WO2023284736A1 (fr) 2023-01-19
WO2023284735A1 (fr) 2023-01-19

Similar Documents

Publication Publication Date Title
JP7144618B2 (ja) バーコード付きガイドｒｎａ構築体を使用する効率的な遺伝子スクリーニングのための組成物及び方法
Nanavaty et al. DNA methylation regulates alternative polyadenylation via CTCF and the cohesin complex
Hou et al. SLE non-coding genetic risk variant determines the epigenetic dysfunction of an immune cell specific enhancer that controls disease-critical microRNA expression
AU2013246909B2 (en) Novel markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the DNA base excision repair pathway
EP3212789B1 (fr) Génétique combinatoire massivement parallèle pour crispr
Xu-Monette et al. Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma
US10633707B2 (en) Markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the DNA base excision repair pathway
WO2019200214A1 (fr) Compositions et méthodes de traitement du cancer
CN111349654B (zh) 使用加标签的向导rna构建体进行高效基因筛选的组合物和方法
Sanghvi et al. Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia
Tellez et al. miR-196b is epigenetically silenced during the premalignant stage of lung carcinogenesis
WO2023284735A1 (fr) Procédés d'identification de gènes sensibles aux médicaments et de gènes pharmacorésistants dans des cellules cancéreuses
Wang et al. CRISPR-Cas9 HDR system enhances AQP1 gene expression
WO2019222212A1 (fr) Édition de gènes pour troubles auto-immuns
WO2023109875A1 (fr) Biomarqueurs pour le traitement du cancer colorectal
US10513732B2 (en) Sequencing methods and kits
Scholz et al. Divergent methylation of CRISPR repeats and cas genes in a subtype ID CRISPR-Cas-system
JP2022502481A (ja) 遺伝的に変異された細胞の死滅誘導組成物及び該組成物を用いた遺伝的に変異された細胞の死滅誘導方法
Xu-Monette et al. MYC mutation profiling and prognostic significance in de novo diffuse large B-cell lymphoma
Menon STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF MiRNA IN COLON CANCER AND THE IDENTIFICATION OF TARGETS BY INSILICO METHODS
JP2022512673A (ja) 制御性ｔ細胞を改変するための組成物および方法
US20220290132A1 (en) Engineered CRISPR/Cas9 Systems for Simultaneous Long-term Regulation of Multiple Targets
WO2023109876A1 (fr) Biomarqueurs pour le traitement du cancer colorectal
Yuan Epigenetic regulatory network of primary brain tumour in adults
Fernandes Neto et al. A fluorescence-based sensor screen identifies MED12 as a potential microsatellite instability regulator in colon cancer